EGFR-Mutated NSCLC: Impact of Subcutaneous Administration on Treatment Experience

In this segment, Dr. Sands invites the panel to discuss how subcutaneous administration may influence treatment experience in EGFR-mutated non-small cell lung cancer, referencing data from the PALOMA-3 trial. Dr. Wakelee and Dr. Cooper highlight that while subcutaneous delivery reduces infusion-related reactions and shortens administration time compared with intravenous therapy, it does not eliminate other clinically relevant toxicities such as rash, edema, and venous thromboembolism. The panel emphasizes that these safety considerations remain important when counseling patients. They also discuss how a shorter administration time may improve clinic workflow and patient convenience, potentially reducing time spent in infusion centers. However, they note that treatment burden is multifactorial and extends beyond administration alone, including ongoing toxicity management and monitoring. Overall, the discussion underscores the importance of balancing convenience with a realistic understanding of safety profiles when integrating new administration approaches into clinical practice in EGFR-mutated NSCLC.